Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT

View Full Paper
Ask AI
Bookmark
Share

Authors

LXLanping XuXZXiaohui ZhangXZXiang‐Yu Zhao

Discussion

Loading...

Member takes

Overview

Multicenter comparison found similar outcomes for blinatumomab, inotuzumab ozogamicin, and CAR-T before HSCT, suggesting close monitoring for CMV reactivation in CAR-T patients.

Key Points

  • To compare the efficacy and safety of different bridging therapies in patients with relapsed/refractory B-ALL prior to allo-HSCT.
  • Multicenter retrospective study of R/R B-ALL patients receiving blinatumomab, inotuzumab ozogamicin, or CAR-T therapy before HSCT.
  • Multivariable analyses conducted using Cox proportional hazards model and R software.
  • Comparison of neutrophil and platelet engraftment and survival outcomes post-transplantation.
  • No significant differences in neutrophil or platelet engraftment among therapy groups.
  • Similar overall survival and disease-free survival rates observed across treatments.
  • Car-T recipients showed a significantly higher incidence of post-HSCT CMV reactivation.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5fahttps://doi.org/10.1182/blood-2025-4298
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pre-transplant MRD negativity and TP53 mutation status determine survival after CAR-T therapy bridged to allo-HSCT for refractory/relapse B-ALL.2026
  2. 2Resource-adapted immunotherapy bridging to achieve measurable residual disease negativity before allogeneic hematopoietic stem cell transplantation in high-risk acute lymphoblastic leukemia: A single-center real-world experience2026
  3. 3Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia2025 · 2 citations
  4. 4CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia2024 · 7 citations
  5. 5Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study2026